YOLFTbeta
Amplia Therapeutics Ltd

Amplia Therapeutics Ltd

ATX · AU · Healthcare / Biotechnology

0.09AUD+0.00 (+4.65%)

Price History

Full chart

Market Stats

Previous Close0.086
Open0.086
Day Range0.084 – 0.09
52-Week Range0.10 – 0.275
Volume741.84K
Market Cap56.46M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.02
Dividend Yield0.00%
Beta-0.40
50-Day Avg0.1339
200-Day Avg0.1402

About

Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in phase 2b clinical trial for pancreatic cancer; and treatment of ovarian cancer. It also develops AMP886 for application in oncology and chronic fibrosis indications. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Christopher J. Burns B.Sc., BSc(Hons), Ph.D.
  • Employees0
  • Headquarters90 William Street, Melbourne, VIC, Australia, 3000, Australia
  • Websitehttps://www.ampliatx.com

Leadership

  • Dr. Christopher J. Burns B.Sc., BSc(Hons), Ph.D.CEO, MD & Director · b. 1965
  • Mr. Hamish George B.Com., C.A.Chief Financial Officer
  • Ms. Rhiannon Jones B.Sc., Ph.D.Chief Operating Officer
  • Dr. Jason Lickliter MBBSChief Medical Officer
  • Mr. Andrew John Cooke FAICS, FCIS, FGIA, L.L.B., MAICDCompany Secretary · b. 1960

Financials

Income Statement

Currency: AUD2010-03-312011-03-312012-03-312013-03-312014-03-312015-03-312016-03-312017-03-312018-03-312019-03-312020-03-312021-03-312022-03-312023-03-312024-03-312025-03-312026-03-31
Total Revenue-----30.31K2.26M1.80M580.29K50.47K34.23K1.53M1.98M1.19M4.45M3.78M-
Growth (%)------+7367.47%-20.55%-67.73%-91.30%-32.19%+4380.44%+29.33%-40.03%+274.34%-15.03%-
Cost of Revenue1.41M1.33M1.31M236.53K167.28K237.99K568.42K36.95K20.16K1.59K8016723.21K73.37K441.99K210.57K92.14K
Gross Profit-1.41M-1.33M-1.31M-236.53K-167.28K-207.68K1.69M1.76M560.13K48.88K33.42K1.53M1.98M1.12M4.01M3.57M-92.14K
Gross Margin------685.21%74.89%97.94%96.53%96.85%97.66%99.96%99.84%93.83%90.07%94.43%-
Operating Expense2.29M1.40M2.15M2.79M3.92M5.19M9.01M10.73M5.39M1.98M2.29M5.41M5.62M8.59M8.44M10.09M13.09M
Operating Income-3.70M-2.73M-3.46M-3.03M-4.09M-5.40M-7.31M-8.97M-4.83M-1.93M-2.26M-3.88M-3.64M-7.48M-4.42M-6.52M-13.18M
Operating Margin------17810.70%-323.04%-498.80%-831.65%-3816.50%-6600.40%-252.69%-183.69%-628.45%-99.38%-172.22%-
EBITDA-2.49M-720.75K-1.50M-1.48M-2.62M-3.69M-4.45M-7.10M-4.30M-1.92M-2.25M-3.81M-3.64M-7.26M-4.48M-6.78M-13.09M
EBITDA Margin------12168.95%-196.57%-394.89%-741.77%-3801.64%-6582.22%-248.71%-183.55%-610.65%-100.70%-179.24%-
Net Income-4.06M-2.44M-3.25M-3.39M-4.50M-5.24M-4.94M-7.08M-4.30M-1.87M-2.22M-2.28M-3.64M-6.24M-4.50M-6.57M-7.71M
Net Income Margin------17278.70%-218.40%-393.54%-740.59%-3704.79%-6484.57%-148.75%-183.74%-524.80%-101.14%-173.69%-
R&D1.08M966.75K1.29M773.39K648.00K2.04M4.75M6.04M3.22M678.42K1.07M2.21M3.77M4.69M5.80M7.53M9.08M
R&D as % of Total Revenue-----6733.97%209.70%335.69%555.66%1344.10%3131.09%144.23%190.19%394.03%130.36%198.97%-
Interest Expense165.57K391.89K447.37K0493.00K1212000001.15K53.85K78.48K55.88K17.37K
Interest Expense % of Total Revenue-----0.04%0.00%0.00%0.00%0.00%0.00%0.00%0.06%4.53%1.76%1.48%-

Balance Sheet

Currency: AUD2010-03-312011-03-312012-03-312013-03-312014-03-312015-03-312016-03-312017-03-312018-03-312019-03-312020-03-312021-03-312022-03-312023-03-312024-03-312025-03-312026-03-31
Total Assets8.21M7.85M5.74M11.43M10.18M5.32M5.03M7.54M2.64M9.19M9.12M10.88M24.48M18.68M14.85M22.94M41.44M
Total Liabilities2.23M1.78M2.55M191.00K403.73K452.90K1.03M907.87K279.42K526.86K510.62K539.13K2.64M2.85M3.43M1.91M1.97M
Total Equity5.98M6.07M3.19M11.23M9.77M4.87M4.00M6.63M2.36M8.66M8.61M10.34M21.85M15.84M11.42M21.02M39.47M
Cash1.11M2.08M1.17M8.36M7.94M4.09M3.20M5.76M2.23M1.24M1.11M1.85M14.61M9.26M3.39M10.86M27.85M
Total Debt2.07M1.60M2.07M3.07M--10.15K10.28K10.61K10.61K-2.10M4.28M2.27M1.59M13.89K341.11K
Net Debt960.80K-483.54K903.07K-5.29M-7.94M-4.09M-3.19M-5.75M-2.22M-1.23M-1.11M-1.85M-12.51M-6.99M-1.80M-10.85M-27.51M

Cash Flow

Currency: AUD2010-03-312011-03-312012-03-312013-03-312014-03-312015-03-312016-03-312017-03-312018-03-312019-03-312020-03-312021-03-312022-03-312023-03-312024-03-312025-03-312026-03-31
Operating Cash Flow-2.04M-1.60M-1.27M-1.75M-1.60M-3.98M-4.71M-6.16M-3.55M-987.35K-2.09M-2.92M-4.40M-5.29M-5.13M-6.89M-8.73M
Investing Cash Flow-7.36K4.90K-1.91K6.83K-1.00K-25.00K-39.06K-46.53K1.86K-3.19K-5.00K-5.35K-26.64K-58.42K-2.23K-2.07K-96.22K
Financing Cash Flow1.67M2.67M234.99K714.55K9.43M-2.10K4.01M8.72M-12.91K-12.14K1.96M3.66M17.19M-84.22K-772.98K14.32M25.94M
Capital Expenditure12.19K6.46K6.76K01.00K25.00K39.06K46.53K4.42K3.19K5.00K5.35K14.40K17.63K2.23K2.07K33.31K
Free Cash Flow-2.05M-1.61M-1.28M-1.75M-1.61M-4.00M-4.75M-6.21M-3.55M-990.54K-2.09M-2.92M-4.42M-5.31M-5.13M-6.89M-8.77M
Dividends Paid----2.25M--0----16.01M----
FCF to OCF100.60%100.40%100.53%100.00%100.06%100.63%100.83%100.76%100.12%100.32%100.00%100.18%100.33%100.33%100.04%100.03%100.38%
Dividend Paid to FCF-----140.43%--0.00%-----362.45%----

Earnings

Report DateJun 22, 2016Nov 29, 2016Jun 22, 2017Nov 30, 2017Jun 20, 2018Nov 28, 2018May 29, 2019Nov 29, 2019May 29, 2020Nov 27, 2020May 31, 2021Nov 24, 2021May 29, 2022Nov 17, 2022Nov 27, 2024May 30, 2025Nov 25, 2025
EPS Estimate0.000.000.000.000.000.000.000.000.00-0.00--0.000.000.00-
EPS Actual-0.15-0.17-0.16-0.11-0.19-0.02-0.03-0.02-0.03-0.01-0.02-0.01-0.01-0.02-0.01-0.01-0.01
Surprise-----------------
Timing-------------After-hours--Pre-market

Key Statistics & Ratios

Market Cap56.46M
Enterprise Value34.08M
Trailing P/E0.00
Forward P/E0.00
Price / Sales11.78
Price / Book1.56
EPS-0.02
Book Value0.077
Revenue (TTM)4.79M
Gross Profit (TTM)4.41M
EBITDA-8.38M
Profit Margin-160.86%
Operating Margin-185.70%
Return on Equity-25.48%
Return on Assets-16.29%
Shares Outstanding513.31M
Shares Float414.17M
Beta-0.40
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Nov 1, 2024352:345
  • Apr 18, 2024427:415
  • Nov 15, 202195:94
  • Jul 3, 202040:37
  • Apr 30, 20181:10
  • Jun 15, 2016570:563